Angiogenesis as a target for cancer therapy.
Antiangiogenic drugs are unique for having highly specific targets while carrying the potential to be effective against a wide variety of tumors. Moreover, some of the major limitations of cytotoxic therapies likely will be avoided by this entirely new class of anticancer weapons. After the realization of the potential advantages of antiangiogenic therapy, the field of angiogenesis research is growing exponentially. Still, there is much to learn about the machinery that tumors use to recruit new blood vessels, and the results of the clinical trials will show the best way to apply that knowledge for cancer therapy.
Kaban
Kerim
K
Department of Thoracic Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Herbst
Roy S
RS
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D043168:Angiostatins; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015687:Cell Hypoxia / Q000502:physiology; D002648:Child; D002986:Clinical Trials as Topic; D003094:Collagen / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D043169:Endostatins; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D036342:Ephrins / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors / Q000502:physiology; D008025:Ligases / Q000502:physiology; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D010446:Peptide Fragments / Q000502:physiology; D010958:Plasminogen / Q000502:physiology; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D036081:Receptors, Eph Family / Q000037:antagonists & inhibitors / Q000502:physiology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology; D019699:Thrombospondins / Q000502:physiology; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D043169:Endostatins; D036342:Ephrins; D006133:Growth Substances; D039302:Integrin alphaVbeta3; D061965:Matrix Metalloproteinase Inhibitors; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D011480:Protease Inhibitors; D017978:Receptors, Growth Factor; D019699:Thrombospondins; D025521:Tumor Suppressor Proteins; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D036081:Receptors, Eph Family; D020782:Matrix Metalloproteinases; D008025:Ligases; C497446:VHL protein, human